Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Net Income (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Net Income for 6 consecutive years, with -$31.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income fell 58.02% to -$31.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$113.6 million, a 64.69% decrease, with the full-year FY2025 number at -$113.6 million, down 64.69% from a year prior.
  • Net Income was -$31.9 million for Q4 2025 at Janux Therapeutics, down from -$24.3 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$2.3 million in Q1 2021 to a low of -$33.9 million in Q2 2025.
  • A 5-year average of -$16.8 million and a median of -$16.4 million in 2022 define the central range for Net Income.
  • Peak YoY movement for Net Income: plummeted 757.17% in 2021, then soared 65.96% in 2024.
  • Janux Therapeutics' Net Income stood at -$13.4 million in 2021, then decreased by 19.75% to -$16.1 million in 2022, then increased by 26.81% to -$11.8 million in 2023, then tumbled by 71.93% to -$20.2 million in 2024, then plummeted by 58.02% to -$31.9 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Net Income are -$31.9 million (Q4 2025), -$24.3 million (Q3 2025), and -$33.9 million (Q2 2025).